ArticleFrontiers in genetics2025
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticle-Based Targeted Drug-Delivery Systems for Cardiomyopathy: Mechanisms and Therapeutic Advances.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to elucidate the pathogenicity of the Methods: Protein 3D modeling predicted structural alterations induced by the mutation. Results: Bioinformatic analysis revealed disruption of hydrogen bonding and electrostatic potential at the mutation site. Conclusion: This study establishes a novel link between TPM1-p.E181K and sporadic RCM. We demonstrate that its pathogenesis is mediated through a cascade of events: calcium dyshomeostasis leads to the suppression of CaMKII/HDAC4 phosphorylation, which subsequently causes sarcomere structural disruption, and ultimately results in myocardial hypercontractility. This identified signaling axis may represent a promising therapeutic target for RCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.